LUMO - Total Utang marang Modal Lumos Therapeutics

Logo perusahaan publik Lumos Pharma, Inc. (LUMO)

Lumos Pharma, Inc. (LUMO) faces challenges in the form of a potential failure of LUM-201 trials and the necessity of regular capital raises to fund its research. The logistics framework relies on stable component procurement contracts. The stock price history reflects a total debt-to-equity ratio of 1.24. The business develops tablet-based therapies for growth hormone deficiency, sparing children from painful injections.

LUMO: Total Utang marang Modal Lumos Pharma 04.07.2022 - 21.12.2024

Rincian analitis perusahaan Lumos Pharma, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Lumos Pharma|LUMO - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Lumos Pharma|LUMO - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Lumos Pharma|LUMO - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku lumos-pharma.com|LUMO - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Lumos Pharma, Inc.|LUMO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Lumos Pharma, Inc.|LUMO - Gunggung utang perusahaan|Utang marang nilai buku Lumos Pharma|LUMO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lumos Pharma|Rasio cepet lumos-pharma.com
- informasi bathi lan kelipatan valuasi:
LUMO - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Lumos Pharma
Barang utama Lumos Therapeutics

This ratio is calculated as the ratio of total liabilities to net equity, measuring the business's dependence on debt financing and solvency risks. Optimizing the debt-to-equity ratio is critical for Lumos Pharma, Inc. (LUMO), as the capital-intensive implementation of AI models and robotic laboratories requires a balance between borrowed funds and financial stability during the development of rare disease therapies.

Analisis pesaing Lumos Pharma, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal BMEA|Utang marang Ekuitas QNCX (quincetx.com)|Utang marang Ekuitas Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Utang marang Modal|ATPC - Utang marang Ekuitas|PLUR: Utang marang Ekuitas|SYBX: Total Utang marang Modal|LPCN - Koefisien Total Utang marang Modal|Utang marang Ekuitas Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Galecto Corp (GLTO)|Rasio Total Utang marang Ekuitas Carmell Therapeutics CTCX|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|radiuspharm.com - Utang marang Ekuitas